Avalyn is reimagining the future of pulmonary fibrosis treatment with a pipeline of new inhaled formulations of approved medicines designed to reduce systemic exposure and deliver medication directly to the site of disease. Pulmonary fibrosis is characterized by scarring of lung tissue, decline in lung function, and reduced exercise capacity and quality of life, and is associated with increased mortality. Currently approved therapeutic options slow pulmonary fibrosis progression but are associated with significant toxicities that restrict their use and dosing. Avalyn’s inhaled approach is designed to tackle the underlying pathophysiology of pulmonary fibrosis at its source and reduce systemic exposure and deliver medication directly to the site of disease. AP01, an optimized inhaled formulation of pirfenidone administered via nebulization, is currently being studied in the ongoing MIST Phase 2b study in progressive pulmonary fibrosis (PPF). AP01 has been assessed in over 150 individuals with different forms of pulmonary fibrosis and demonstrated clinical proof-of-concept with promising signals of efficacy and safety, supporting continued clinical development. The company completed two Phase 1 studies for AP02, inhaled nintedanib administered via nebulization, and is currently running a Phase 2 AURA study in patients with idiopathic pulmonary fibrosis (IPF). For more information, please visit avalynpharma.com and follow us on LinkedIn.
Accessia Health
Accessia Health, a nonprofit patient assistance organization, supports individuals living with rare or chronic health conditions. Through our 80+ disease programs we offer case management, financial assistance, education, and other related services. Our holistic, inclusive, and outcomes-focused approach addresses unmet needs and improves access to health care.
4DMedical
4DMedical is a global leader in innovative respiratory and cardiopulmonary imaging software. Our SaaS solutions deliver non-invasive, regional, and lobar quantitative lung function analysis—giving pulmonologists and clinicians the power to act sooner and with objective data for patients with unexplained dyspnea, asthma, COPD, and other lung diseases. We also support early intervention with low-dose lung health screenings and physician-customized smoking cessation tools to help prevent disease progression. 4DMedical’s CT:VQ™ is the world’s first and only non-contrast post-processing technology that transforms routine chest CT scans into detailed, quantitative maps of lung ventilation (V) and perfusion (Q), all without injected contrast or radioisotopes. CT:VQ™ seamlessly fits into your existing workflow, delivering results directly for rapid interpretation—all from the CT you already order. You can act sooner with objective perfusion data—from the CT you already order. Enhance patient care with actionable functional data from every chest CT—accelerating your path from suspicion to confident clinical decision. | 4DMedical is a global leader in innovative respiratory and cardiopulmonary imaging software. Using advanced, non-invasive CT imaging technology, our SaaS offerings provide non-invasive, regional and lobar quantitative lung function analysis for unparalleled insights into cardiopulmonary health. With a single CT lung scan, 4DMedical provides automated, quantitative analysis that equips radiologists with detailed insights to support ordering physicians in delivering optimal patient care. Now available: CT:VQ™ is the world’s first and only non-contrast post-processing technology that transforms routine chest CT scans into quantitative, lobar ventilation (V) and perfusion (Q) maps—without contrast media, inhaled agents, or added scan time. Results are automatically delivered to PACS, ready for radiologist interpretation alongside the source CT images. For Radiologists: – One modality, one department: Complete pulmonary imaging with no new hardware or workflow steps – Add objective, functional metrics to every routine CT – Improve reporting consistency and inter-reader reproducibility – Automated, quantitative reporting and seamless PACS integration – Peer-reviewed, proven correlation with spirometry and radiologist-based metrics – Enhance your CT utility—structure and function, together in a single exam With 4DMedical, radiologists can deliver both structural and functional lung, and cardiac assessment from standard CT, enhancing diagnostic confidence, improving report value, and streamlining workflow efficiency.